Patents Issued in March 23, 2017
  • Publication number: 20170079938
    Abstract: The use of tapentadol for the manufacture of a medicament comprising at least one administration unit A containing dose a of tapentadol and at least one administration unit B containing dose b of tapentadol, where dose a<dose b, for the treatment of pain.
    Type: Application
    Filed: December 5, 2016
    Publication date: March 23, 2017
    Inventors: Claudia LANGE, Ferdinand ROMBOUT
  • Publication number: 20170079939
    Abstract: Personal care compositions, such as oral medication compositions containing a flavor system comprising one or more coolants. The pleasant cool sensation provided by a coolant is enhanced in terms of quicker onset, greater intensity, impact or longer duration, which improves appeal and acceptability of the compositions to consumers.
    Type: Application
    Filed: September 12, 2016
    Publication date: March 23, 2017
    Inventors: John Christian Haught, Michael Reilly, Steven Hamilton Hoke, Qingxin Lei, Yakang Lin, Koti Tatachar Sreekrishna, Ashraf Traboulsi
  • Publication number: 20170079940
    Abstract: Provided is a novel transdermal absorption preparation containing silodosin or tamsulosin, or salt thereof as an active ingredient, wherein the transdermal absorption preparation is capable of keeping a dissolved state for a long time, as well as has a high permeability to a skin, and can effectively and sustainably exert the transdermal absorbability. A transdermal absorption preparation containing the transdermal absorption preparation comprises an acrylic pressure-sensitive adhesive that comprises a copolymer of at least one (meth)acrylic acid monomer and at least one vinyl monomer and that contains a carboxyl group, and at least one transdermal absorption promoting agent selected from the group consisting of oleyl alcohol, lauryl alcohol, and lauromacrogol.
    Type: Application
    Filed: May 20, 2015
    Publication date: March 23, 2017
    Applicant: TEIKOKU SEIYAKU CO., LTD.
    Inventors: Satoshi KAWAKAMI, Taiki SHIBATA, Manabu SOGABE
  • Publication number: 20170079941
    Abstract: The present invention provides a method for inhibiting melanogenesis, promoting collagen production, and promoting wound healing in the skin of a subject in need thereof, comprising administering to the subject an effective amount of a compound represented by formula (I). The compound of the present invention can inhibit melanin formation, promote collagen production and facilitate wound repair. Therefore, the compound can be utilized to manufacture compositions for skin whitening, anti-aging, and wound healing. The present invention also provides a method of preparing a compound of formula (I).
    Type: Application
    Filed: August 4, 2016
    Publication date: March 23, 2017
    Inventors: Yung-Hsiang Lin, Hsiang-Ling Su
  • Publication number: 20170079942
    Abstract: The present invention aims to provide a growth inhibitor for cancer stem cells resistant to existing anticancer drug therapies, which growth inhibitor acts on the cells through growth inhibition and apoptosis. The growth inhibitor for cancer stem cells contains a retinoid agonist, preferably tamibarotene, alone or in combination with a rexinoid agonist, preferably bexarotene, as an effective component(s). The growth inhibitor for cancer stem cells enhances the effects of various anticancer drugs when the growth inhibitor is used in combination with the anticancer drugs.
    Type: Application
    Filed: May 20, 2015
    Publication date: March 23, 2017
    Applicants: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, TMRC Co., Ltd.
    Inventors: Akira KURISAKI, Ying Ying WANG, Hitomi TAKADA, Hisao EKIMOTO
  • Publication number: 20170079943
    Abstract: Embodiments of the present invention relate generally the use of certain compositions, e.g., compositions comprising a glutathione precursor and a selenium source, in the therapy of viral diseases and/or reducing the incidence of viral diseases. Related embodiments of the present invention relate to treatment and/or reducing the incidence of respiratory ailments caused by respiratory syncytial virus (RSV) or hemorrhagic fever (EHF) caused by Ebola viruses (EBV) or Marburg virus. Yet in other embodiments, the invention relates to reducing metal toxicity in a biological system, which involves contacting the biological system with a composition comprising a glutathione precursor and a selenium source, optionally together with a chelating agent, an antioxidant, a metallothioneine protein or a fragment of metallothioneine.
    Type: Application
    Filed: December 2, 2016
    Publication date: March 23, 2017
    Inventor: Albert Crum
  • Publication number: 20170079944
    Abstract: The present invention relates to a tall oil fatty acid which is modified by saponification for use in the prevention of growth of harmful bacteria in the animal digestive tract and/or in the prevention of intestinal disorders. The invention further relates to a feed supplement and a feed composition comprising tall oil fatty acid which is modified by saponification.
    Type: Application
    Filed: December 7, 2016
    Publication date: March 23, 2017
    Applicant: Hankkija Oy
    Inventors: Juhani VUORENMAA, Hannele KETTUNEN
  • Publication number: 20170079945
    Abstract: The present disclosure relates to methods and compositions for suppressing the growth of microorganisms on selected areas of the skin for an extended period of time, such as one hour, twenty four hours, seventy two hours, or longer. An area of the skin is selected for the suppression of the growth of microorganisms and a microorganism growth suppressing agent is topically applied to the selected area of the skin. The microorganism growth suppressing agent may be comprised in a pharmacologically acceptable vehicle such as an emulsion or soap. The microorganism growth suppressing agent comprises free conjugated fatty acid such as conjugated linoleic acid.
    Type: Application
    Filed: December 6, 2016
    Publication date: March 23, 2017
    Inventor: David G. Changaris
  • Publication number: 20170079946
    Abstract: A medical composition for reducing the rate of new-onset diabetes caused by administration of a statin or for inhibiting an increase in blood glucose level by administration of a statin, the composition containing at least one ingredient selected from the group consisting of icosapentaenoic acid and pharmaceutically acceptable salts or esters thereof as an inactive ingredient.
    Type: Application
    Filed: November 30, 2016
    Publication date: March 23, 2017
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Masahiko OHTA, Shinichi OIKAWA, Mitsuhiro YOKOYAMA, Hideki ORIGASA, Masunori MATSUZAKI, Yuji MATSUZAWA, Yasushi SAITO
  • Publication number: 20170079947
    Abstract: Flavonoid compositions containing the flavonoid quercetin and/or derivatives of quercetin are disclosed. The flavonoid compositions are formulated to improve the bioavailability of quercetin. Also provided herein are methods for improving athletic performance, improving cardiovascular health, and aiding in immune response and methods of improving athletic performance, improving bone health, preventing fatigue, reducing recovery time after exercise, countering oxidative stress, and/or boosting energy.
    Type: Application
    Filed: September 22, 2016
    Publication date: March 23, 2017
    Inventor: Kurt Richards
  • Publication number: 20170079948
    Abstract: The present disclosure is directed to compositions comprising bryostatin-1, and methods comprising administering a composition comprising bryostatin-1, to treat Niemann-Pick Type C in a subject in need thereof.
    Type: Application
    Filed: March 27, 2015
    Publication date: March 23, 2017
    Inventor: Daniel L. ALKON
  • Publication number: 20170079949
    Abstract: Aerosol formulations comprising glycopyrronium chloride in combination with formoterol may be administered by means of a pressurized metered dose inhaler (pMDI) for the prevention or treatment of chronic obstructive pulmonary disease. The formulation further comprises a HFA propellant, a co-solvent, and an amount of inorganic acid sufficient to stabilize both the glycopyrronium chloride and the formoterol components. Optionally, the formulation may further comprise beclometasone dipropionate.
    Type: Application
    Filed: December 5, 2016
    Publication date: March 23, 2017
    Inventors: Sauro BONELLI, Francesca USBERTI, Enrico ZAMBELLI
  • Publication number: 20170079950
    Abstract: In certain embodiments, this disclosure relates to methods of treating or preventing HvGD comprising administering an effective amount of indole-2-carboxyaldehyde, indole-3-carboxyaldehyde, or derivative to a subject in need thereof. In certain embodiments, this disclosure relates to methods of treating a subject with a hematological malignancy or other cancer comprising transplanting allogenic bone marrow or stem cells in combination with administering an effective amount of an indole-2-carboxyaldehyde, indole-3-carboxyaldehyde, or derivative thereof to a subject in need thereof.
    Type: Application
    Filed: September 17, 2016
    Publication date: March 23, 2017
    Inventors: Daniel Kalman, Edmund K. Waller, Cynthia R. Giver, Alyson Swimm, Sravanti Rangaraju
  • Publication number: 20170079951
    Abstract: The present specification discloses compositions comprising a pharmaceutical composition to reduce or maintain LDL and/or cholesterol levels in an individual and a plurality of therapeutic compounds to increase or maintain HDL levels in an individual. The present specification also discloses a treatment protocol wherein a pharmaceutical composition is administered to an individual on a schedule wherein the pharmaceutical composition is provided for a period of time and then not provided to the individual and this treatment protocol is repeated for the term of the individual's treatment.
    Type: Application
    Filed: November 30, 2016
    Publication date: March 23, 2017
    Applicant: Biocopea Limited
    Inventors: John Brew, Robin Mark Bannister
  • Publication number: 20170079952
    Abstract: A synthetic molecule 4210 and a therapeutic use of a synthetic small molecule 4210 for treating viral infections, especially encephalitic alphavirus infections. The compound 4210 showed antiviral efficacy by up regulation type 1 interferon (IFN) specifically IFN-?. The compound 4210 was designed and synthesized by a structure-based approach targeting intracellular adaptor protein, myeloid differentiation primary response protein 88 (MyD88). Besides having an antiviral effect, the compound 4210 also demonstrated therapeutic efficacy for treating inflammatory syndrome associated with Gram positive bacterial infections such as exposure to staphylococcal enterotoxin B (SEB) induced toxic shock syndrome (TSS) in mice and can potentially be used in clinical set up for treating sepsis and septic shock.
    Type: Application
    Filed: December 5, 2016
    Publication date: March 23, 2017
    Applicant: The Government of the United States, as represented by the Secretary of the Army
    Inventors: Kamal U. Saikh, Julius M. Rebek, JR., Pamela J. Glass
  • Publication number: 20170079953
    Abstract: The invention relates to the use of melatonin, either alone or in combination with at least one compound selected from the group consisting of L-arginine, a physiologically acceptable salt thereof, one or more other physiologically acceptable compounds associated with the synthesis of nitric oxide and mixtures thereof, for the manufacture of a medicament for the therapeutic treatment, prophylactic treatment and/or prevention of postoperative infectious and/or non-infections complications induced by surgical interventions wherein the infectious complications may be pneumonia, wound infection (wound dehiscence), intra-abdominal abscess, and urinary tract infections (UTI) or wherein the non-infectious complication may be anastomotic leak, a pharmaceutical formulation comprising melatonin and at least one compound selected from the group consisting of L-arginine, a physiologically acceptable salt thereof, one or more other physiologically acceptable compounds associated with the synthesis of nitric oxide and mixt
    Type: Application
    Filed: May 13, 2016
    Publication date: March 23, 2017
    Applicant: NUTRI-FIT GMBH & CO. KG
    Inventor: Heinz SCHNEIDER
  • Publication number: 20170079954
    Abstract: Provided herein are pharmaceutically acceptable salts of 3,5-diaminopyrazoles, for example, pharmaceutically acceptable salts of compounds of Formula IA, that are useful for modulating regulated-in-COPD kinase activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a RC kinase-mediated disorder, disease, or condition.
    Type: Application
    Filed: November 30, 2016
    Publication date: March 23, 2017
    Inventors: Tai Wei LY, Erik Dean RAAUM
  • Publication number: 20170079955
    Abstract: Disclosed herein are methods, compounds, such as bindaret, and compositions that are useful for the diagnosis, treatment, or prevention of an ocular disorder, including the discovery of agents that are efficacious against these disorders. Also included is the use of a fluorescent compound in an amount effective to indicate the presence of said ocular disorder in order to determine the efficacity of said compounds used in the diagnosis, treatment or prevention of said ocular disorders.
    Type: Application
    Filed: May 15, 2015
    Publication date: March 23, 2017
    Inventor: Shelley Romayne Boyd
  • Publication number: 20170079956
    Abstract: Disclosed herein is a method of upregulating regulatory T cells, and treating diseases that would benefit from such upregulation, by administering an alpha-2 receptor agonist.
    Type: Application
    Filed: December 7, 2016
    Publication date: March 23, 2017
    Inventors: Daniel W. Gil, John E. Donello, Veena Viswanath, Lauren M.B. Luhrs
  • Publication number: 20170079957
    Abstract: The invention features topical formulations comprising an osmotically active agent and/or a vasoconsgtrictor and/or an astringent agent for the treatment and prevention of eyelid swelling, and methods of use thereof.
    Type: Application
    Filed: December 1, 2016
    Publication date: March 23, 2017
    Inventors: Matthew Jonathan Chapin, Mark Barry Abelson, Keith Jeffrey Lane, George Minno
  • Publication number: 20170079958
    Abstract: The present invention relates to the use of compounds of general Formula I and pharmaceutically acceptable enantiomers, salts or solvates thereof, for treating pulmonary hypertension in a subject.
    Type: Application
    Filed: May 18, 2015
    Publication date: March 23, 2017
    Inventors: Gaël JALCE, Christophe GUIGNABERT, Morane LE HIRESS, Ly TU, Bernardin AKAGAH
  • Publication number: 20170079959
    Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for eye conditions associated with angiogenesis, for example, intraocular pressure, ocular hypertension, and glaucoma.
    Type: Application
    Filed: September 22, 2016
    Publication date: March 23, 2017
    Inventor: Kevin Gene Peters
  • Publication number: 20170079960
    Abstract: The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitisers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present invention further relates to compounds and agents and compositions thereof for use in the treatment methods.
    Type: Application
    Filed: September 26, 2016
    Publication date: March 23, 2017
    Inventors: Gregory Royce COLLIER, Kenneth Russell WALDER, James Alexander CAMPBELL, Juan-Carlos MOLERO-NAVAJAS, Nicky KONSTANTOPOULOS, Guy Yeoman KRIPPNER
  • Publication number: 20170079961
    Abstract: Described herein is a new oral method for using MK-0677 for detecting growth hormone (GH) deficiency (GHD). Also described is a method of treating growth hormone (GH) deficiency (GHD) in children with a functional hypothalamic-pituitary GH axis.
    Type: Application
    Filed: September 21, 2016
    Publication date: March 23, 2017
    Inventor: Michael Oliver Thorner
  • Publication number: 20170079962
    Abstract: The disclosure teaches counter-intuitive methods for treating stomatitis using oral mTOR inhibiting preparations such as preparations of microcapsules and nanoparticles including an inhibitor of the mammalian target of rapamycin. The methods, preparations and other teachings are useful in various respects, especially for assisting in the treatment, prevention and management of stomatitis in feline subjects and, most especially, the treatment and management of Feline Chronic Gingivo-Stomatitis (FOGS), with secondary applications also related to management of gingivitis and autoimmune mucosal disorders. Disclosed embodiments illustrate multi-week dosing regimens and also address needs for alternative preparations or manufacturing processes that ensure efficacy while improving other performance characteristics such as storage stability, biodistribution, dosage cost, etc.
    Type: Application
    Filed: April 16, 2015
    Publication date: March 23, 2017
    Applicant: Rapamycin Holdings, LLC
    Inventor: Dana M Vaughn
  • Publication number: 20170079963
    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain compounds of the following formula (for convenience, collectively referred to herein as “IP compounds”), which, inter alia, are useful in the treatment of cancer, e.g., cancer characterised by (e.g., driven by) mutant RAS (“mutant RAS cancer”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions in the treatment of cancer, e.g., mutant RAS cancer.
    Type: Application
    Filed: September 1, 2016
    Publication date: March 23, 2017
    Inventors: Caroline Joy SPRINGER, Ion NICULESCU-DUVAZ, Richard MARAIS, Dan NICULESCU-DUVAZ, Alfonso ZAMBON, Delphine MENARD
  • Publication number: 20170079964
    Abstract: Methods for manufacturing and using a pharmaceutical composition for reducing the frequency of urination is disclosed. The pharmaceutical composition comprises an analgesic agent and zolpedim.
    Type: Application
    Filed: December 2, 2016
    Publication date: March 23, 2017
    Inventor: David A. DILL
  • Publication number: 20170079965
    Abstract: The present invention relates to indolizine compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.
    Type: Application
    Filed: December 6, 2016
    Publication date: March 23, 2017
    Inventors: Srinivasa R. KARRA, Andreas GOUTOPOULOS
  • Publication number: 20170079966
    Abstract: It has been shown that Compound 1 unexpectedly and potently inhibits TIE2 kinase, and that Compound 1 inhibits drug resistance mechanisms in both the tumor and in the surrounding microenvironment through balanced inhibition of TIE2, MET, and VEGFR2 kinases. Thus, Compound 1 provides a single therapeutic agent able to address multiple hallmarks of cancer by inhibiting TIE2, MET, and VEGFR2 kinases in the tumor microenvironment [Hanahan 2011]. Through its balanced inhibitory potency vs TIE2, MET, and VEGFR2, Compound 1 provides an agent which inhibits three major tumor (re)vascularization and resistance pathways (ANG, HGF, VEGF) and blocks tumor invasion and metastasis. Compound 1 exhibits anti-tumor activity alone and in combination with other targeted agents or chemotherapy.
    Type: Application
    Filed: October 14, 2015
    Publication date: March 23, 2017
    Inventors: Daniel L. FLYNN, Michael D. KAUFMAN, Bryan D. SMITH
  • Publication number: 20170079967
    Abstract: The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine ?7 receptor.
    Type: Application
    Filed: December 6, 2016
    Publication date: March 23, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Jorgen Eskildsen, Anette Graven Sams, Ask Puschl
  • Publication number: 20170079968
    Abstract: The present disclosure is directed to antiviral compounds directed against the papilloma virus, to pharmaceutical compositions containing them, to their preparation method and synthesis intermediates, as well as to their use for treating or preventing an infection by the papilloma virus. The present method thus provides an efficient way of treating patients that have lesions associated with an infection by the papilloma virus.
    Type: Application
    Filed: September 26, 2016
    Publication date: March 23, 2017
    Inventors: Marta BLUMENFELD, Delphine COMPERE, Jean-Michel GAUTHIER
  • Publication number: 20170079969
    Abstract: The disclosure relates to improved methods of administering pirfenidone therapy when ciprofloxacin is administered concomitantly.
    Type: Application
    Filed: December 1, 2016
    Publication date: March 23, 2017
    Inventor: Williamson Z. Bradford
  • Publication number: 20170079970
    Abstract: The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a method for providing cardioprotection in a subject who experienced a myocardial infarction comprising administering the subject with a therapeutically effective amount of at least one EPAC1 inhibitor.
    Type: Application
    Filed: March 20, 2015
    Publication date: March 23, 2017
    Inventors: Frank LEZOUALC'H, Pierre SICARD, Malik BISSERIER
  • Publication number: 20170079971
    Abstract: The disclosure relates to chemokine CXCR4 receptor modulators and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising compounds disclosed herein or pharmaceutically acceptable salts or prodrugs thereof. In certain embodiments, the compositions disclosed herein are used for managing CXCR4 related conditions, typically prevention or treatment of viral infections such as HIV or for managing cancer.
    Type: Application
    Filed: December 6, 2016
    Publication date: March 23, 2017
    Applicant: EMORY UNIVERSITY
    Inventors: Lawrence J. Wilson, John Wiseman, Dennis C. Liotta, Michael G. Natchus
  • Publication number: 20170079972
    Abstract: The administration of a compound advantageously efficacious as ROS1 inhibitor and its effect on subjects with cancer includes administering a compound having certain structural components such as a quinoline moiety in the backbone and at least one tertiary amine containing moiety in a side chain as well as heteroatoms, in particular oxygen atoms, present in the backbone and the side chain for treating a subject suffering from a disease such as cancer. The presence of such structural components allows for an advantageous interaction with the ROS1 kinase domain, in particular with the hinge region. The administered compounds represent a highly promising opportunity in particular for patients bearing ROS1-dependent cancer. A method for targeting tumor cells harboring an abnormality in ROS1 gene includes contacting a cell with compounds of the present invention as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: October 30, 2015
    Publication date: March 23, 2017
    Inventors: Xiao Jun Yao, Lai Han Leung, Lian Xiang Luo, Liang Liu
  • Publication number: 20170079973
    Abstract: Disclosed is the synthesis procedure for benzazolo[3,2-a]quinolinium chloride salts and the inclusion of chloro-substituent, amino-substituent, and nitro-substituent resulting in several compounds. The compounds are further used as markers due to their fluorescent properties including in hypoxic environments. This disclosure further describes anti-cancer screening of two BQS, namely, 7-benzyl-3-aminobenzimidazo[3,2-a]quinolinium chloride (ABQ-48: NSC D-763307) and the corresponding 7-benzyl-3-nitrobenzimidazo[3,2-a]quinolinium chloride (NBQ 48: NSC D-763303).
    Type: Application
    Filed: September 17, 2015
    Publication date: March 23, 2017
    Applicant: SISTEMA UNIVERSITARIO ANA G. MENDEZ, INC.
    Inventors: Osvaldo Cox, Beatriz Zayas
  • Publication number: 20170079974
    Abstract: The disclosure provides extended release pharmaceutical formulations comprising an opioid,particularly buprenorphine, a biocompatible organic solvent, and, optionally, a glycol, for use in the treatment of pain or opioid dependence. The pharmaceutical formulations are in the form of a pharmaceutical solution.
    Type: Application
    Filed: March 9, 2015
    Publication date: March 23, 2017
    Inventors: Mingxing Zhou, Richard L. Norton
  • Publication number: 20170079975
    Abstract: The present invention relates generally to the co-administration of an opioid agonist compound and an analgesic compound. In addition, the invention relates to, among other things, dosage forms for co-administration of an opioid agonist compound and an analgesic compound, methods for administering an opioid agonist compound and an analgesic compound, compositions comprising an opioid agonist compound and an analgesic compound, dosage forms comprising an opioid agonist compound and an analgesic compound, and so on.
    Type: Application
    Filed: September 1, 2016
    Publication date: March 23, 2017
    Inventors: Timothy A. Riley, Juergen W. Pfeiffer, Hema Gursahani
  • Publication number: 20170079976
    Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.
    Type: Application
    Filed: October 25, 2016
    Publication date: March 23, 2017
    Inventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
  • Publication number: 20170079977
    Abstract: Provided herein are methods of treating a cognitive deficit, including cognitive deficits associated with a Fmr1 genetic defect. More particularly, provided herein are methods in which an effective amount of a MDM2-p53 pathway inhibitor is administered to a subject afflicted with at least one cognitive deficit, whereby administration of the inhibitor improves, enhances, or rescues at least one cognitive deficit in the subject.
    Type: Application
    Filed: September 23, 2016
    Publication date: March 23, 2017
    Inventors: Xinyu Zhao, Yue Li
  • Publication number: 20170079978
    Abstract: A method for enhancing glycemic control and/or insulin sensitivity to a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.
    Type: Application
    Filed: December 2, 2016
    Publication date: March 23, 2017
    Inventors: Robert L. Roden, Richard J. Gorczynski, Michael J. Gerber
  • Publication number: 20170079979
    Abstract: A pharmaceutically acceptable composition and method for solid tumor therapy in a patient in need of such therapy. The composition contains, as the only active agents, the combination of (a) an inhibitor of c-Fos, and (b) an inhibitor of Dusp-1, and optionally (c) an inhibitor of a tyrosine kinase. The composition is administered to the patient in a dosing regimen for a period sufficient to provide therapy for solid tumors.
    Type: Application
    Filed: May 29, 2015
    Publication date: March 23, 2017
    Inventors: Mohammad Azam, Meenu Kesarwani
  • Publication number: 20170079980
    Abstract: The present invention relates to a drying process of BIBW 2992 or the salts thereof, preferably the dimaleate salt, as well as of solid pharmaceutical formulations comprising BIBW2992 or a salt thereof, and to pharmaceutical compositions comprising BIBW 2992 or a salt thereof as the active product ingredient, characterized by a water activity of the formulation of not more than 0.20 or a water content (Karl-Fischer) of not more than 4.2%.
    Type: Application
    Filed: December 7, 2016
    Publication date: March 23, 2017
    Inventor: Albert BARTA
  • Publication number: 20170079981
    Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including novel pharmaceutical formulations thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: December 6, 2016
    Publication date: March 23, 2017
    Inventors: Harisha Atluri, Ching Wah Chong, Robert Kuehl, Cassandra Shu, Pearl Shwe-Cho Tay, James F. Hulvat, Alexander J. McVey, Ryan M. Minikis
  • Publication number: 20170079982
    Abstract: The present invention relates to combinations of compounds comprising HIV integrase inhibitors and other therapeutic agents.
    Type: Application
    Filed: December 1, 2016
    Publication date: March 23, 2017
    Applicant: VIIV HEALTHCARE COMPANY
    Inventor: Mark Richard UNDERWOOD
  • Publication number: 20170079983
    Abstract: Methods of inhibiting a receptor tyrosine kinase in a subject in need thereof. Methods of inhibiting the growth of a tumor cell in a subject in need thereof. Methods of treating pancreatic cancer in a subject in need of treatment for pancreatic cancer. Methods of treating HER2 positive breast cancer in a subject in need of treatment for HER2 positive breast cancer. Methods of treating drug resistant non-small cell lung cancer in a subject in need of treatment for drug resistant non-small cell lung cancer. Each of these methods can include administering to the subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 5, 2016
    Publication date: March 23, 2017
    Inventors: Bhujanga rao ADIBHATLA KALI SATYA, Ramanadham JYOTHI PRASAD, Bollepalli NAGESHWARA RAO, Nannapaneni VENKAIAH CHOWDARY
  • Publication number: 20170079984
    Abstract: The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: September 27, 2016
    Publication date: March 23, 2017
    Inventors: Brian K. Albrecht, Michael Charles Hewitt, Victor S. Gehling, Rishi G. Vaswani
  • Publication number: 20170079985
    Abstract: The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.
    Type: Application
    Filed: September 21, 2016
    Publication date: March 23, 2017
    Inventors: Mark Alan Smith, Carine Claassen-Punt
  • Publication number: 20170079986
    Abstract: Disclosed is a method for treating tumor in a mammalian subject, which comprises administering a combination of (a) an anti-tumor agent and (b) a fatty acid derivative represented by the formula (I): to the subject in need thereof. The application also discloses a method for treating damages, especially gastrointestinal damages including mucositis such as stomatitis induced by an anti-tumor agent, wherein the method comprises administering a fatty acid derivative of formula (I) to the subject who is receiving the anti-tumor agent.
    Type: Application
    Filed: December 7, 2016
    Publication date: March 23, 2017
    Applicant: SUCAMPO AG
    Inventor: Ryuji UENO
  • Publication number: 20170079987
    Abstract: Disclosed are methods of treating or preventing an intestinal disease or disorder comprising administering to a subject a modulator of leucine rich repeat kinase 2 (LRRK2) in an amount effective to treat or prevent an intestinal disease or disorder and methods of determining the susceptibility or risk of a subject to develop an intestinal disease.
    Type: Application
    Filed: May 15, 2015
    Publication date: March 23, 2017
    Inventors: Warren Strober, Ivan J. Fuss, Tetsuya Takagawa, Atsushi Kitani